HALO

Business Context and Reporting Period

Company: Halozyme Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Halozyme is a biopharmaceutical company developing products targeting the extracellular matrix, primarily utilizing its proprietary recombinant human PH20 enzyme (rHuPH20). The company operates through a mix of proprietary product development and strategic collaborations with major pharmaceutical partners, including Roche and Baxter. Key marketed products include HYLENEX (an adjuvant for drug dispersion) and Cumulase (for in vitro fertilization).

Key Financial Metrics

Revenue Composition (2009): Revenues under collaborative agreements totaled approximately $12.7 million (primarily from Roche and Baxter), while product sales (HYLENEX and Cumulase) totaled $0.97 million.

Operating Expenses: Total operating expenses were $72.13 million, driven by Research and Development (R&D) costs of $56.61 million and Selling, General, and Administrative (SG&A) expenses of $15.20 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased by 56% ($4.91 million) compared to 2008. This was primarily driven by a 57% increase in collaborative agreement revenues ($12.7 million vs. $8.1 million) due to amortization of license fees and milestone payments from Roche and Baxter.
• Product Sales: Product sales increased by 36% ($0.26 million) to $0.97 million, attributed to increased sales of HYLENEX and Cumulase.
• Net Loss Expansion: Net loss increased by 20% ($9.71 million) to $58.36 million. This increase was primarily due to higher operating expenses, specifically a 28% rise in R&D expenses ($12.4 million increase) driven by the ultrafast insulin and PEGPH20 programs.
• Liquidity: Cash and cash equivalents increased by $3.75 million to $67.46 million. This was supported by net proceeds of $38.2 million from a June 2009 public offering of common stock and $7.2 million from warrant and option exercises, partially offset by a net cash burn of $40.1 million from operating activities.

Guidance, Outlook, and Risks

Outlook and Capital Needs: Management anticipates a net cash burn of approximately $40.0 to $45.0 million for the year ending December 31, 2010. While current cash resources are sufficient for at least the next twelve months, the company expects to require additional capital in the future to fund operations and product development. A universal shelf registration statement filed in January 2010 allows for the sale of up to $100.0 million in equity or debt securities.

Key Developments:

• Roche Partnership: Commenced a Phase 3 clinical trial for subcutaneous Herceptin (trastuzumab) in October 2009 and a Phase 1 trial for subcutaneous MabThera (rituximab) in September 2009.
• Baxter Partnership: Completed enrollment for the Phase 3 clinical trial of GAMMAGARD LIQUID with rHuPH20 in July 2009. Baxter commercially launched HYLENEX recombinant for pediatric rehydration in October 2009.
• Proprietary Pipeline: Continued investment in the ultrafast insulin program (Phase 1 and 2 studies ongoing) and PEGPH20 (Phase 1 dose-escalation trial ongoing).

Risks and Contingencies:

• Profitability: The company has incurred net losses since inception and may never achieve profitability. Future revenues depend on regulatory approvals and successful commercialization.
• Manufacturing Dependence: Reliance on third-party contract manufacturers (Avid Bioservices and Cook Pharmica) for API production. Any failure to scale up or maintain cGMP status could delay clinical trials or commercialization.
• Regulatory Risk: No proprietary or partnered product candidates are currently in the NDA approval process. Clinical trials are uncertain and costly.
• Partner Performance: Revenue and milestone payments depend on the performance of partners (Roche, Baxter) in meeting clinical, regulatory, and sales milestones.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $67.5 million cash balance against the projected $40-45 million annual burn rate and the timeline for future financing needs.
• Deferred Revenue Recognition: Review the terms of the Roche and Baxter agreements to understand the amortization schedule of the $60.5 million deferred revenue balance and the likelihood of achieving future milestones.
• Clinical Trial Progress: Monitor the status of the Phase 3 subcutaneous Herceptin trial and the Phase 3 GAMMAGARD LIQUID trial, as these are critical for future milestone payments.
• Manufacturing Scale-Up: Assess the progress of Cook Pharmica in obtaining cGMP approval and scaling production to meet Roche partnership obligations.
• Product Sales Growth: Track the commercial uptake of HYLENEX following its October 2009 launch to determine if product sales can grow beyond the current minimal levels.